Media coverage
20
Media coverage
Title Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB 011, an Allogeneic Anti BCMA CAR T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet Market News Publishing Country/Territory United States Date 30/03/23 Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing Of First Patient In The Cammouflage Phase 1 Trial Of CB-011, An Allogeneic Anti-BCMA CAR-T Cell Therapy For The Treatment Of Relapsed Or Refractory Multiple Myeloma Media name/outlet MENAFN -Press Releases (English) Country/Territory Jordan Date 29/03/23 Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myelom Media name/outlet Street Insider Country/Territory United States Date 29/03/23 URL https://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Announces+Dosing+of+First+Patient+in+the+CaMMouflage+Phase+1+Trial+of+CB-011%2C+an+Allogeneic+Anti-BCMA+CAR-T+Cell+Therapy+for+the+Treatment+of+Relapsed+or+Refractory+Multiple+Myelom/21432560.html Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet ADVFN UK Country/Territory United Kingdom Date 29/03/23 URL https://uk.advfn.com/stock-market/NASDAQ/CRBU/share-news/Caribou-Biosciences-Announces-Dosing-of-First-Pati/90629575 Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet Yahoo! Finance Country/Territory United States Date 29/03/23 URL https://finance.yahoo.com/news/caribou-biosciences-announces-dosing-first-120000815.html Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet MarketScreener.com Country/Territory United States Date 29/03/23 URL https://www.marketscreener.com/quote/stock/CARIBOU-BIOSCIENCES-INC-125041251/news/Caribou-Biosciences-Announces-Dosing-of-First-Patient-in-the-CaMMouflage-Phase-1-Trial-of-CB-011-an-43368634/ Persons Sundar Jagannath Title Caribou Biosciences : Regulation FD Presentation - Form 8-K Media name/outlet MarketScreener.com Country/Territory United States Date 29/03/23 URL https://www.marketscreener.com/quote/stock/CARIBOU-BIOSCIENCES-INC-125041251/news/Caribou-Biosciences-Regulation-FD-Presentation-Form-8-K-43368812/ Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet Market Newsdesk Country/Territory United States Date 29/03/23 URL https://www.marketnewsdesk.com/index.php/caribou-biosciences-announces-dosing-of-first-patient-in-the-cammouflage-phase-1-trial-of-cb-011-an-allogeneic-anti-bcma-car-t-cell-therapy-for-the-treatment-of-relapsed-or-refractory-multiple-myelom/ Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet Yahoo! Sports Country/Territory United States Date 29/03/23 URL https://ca.sports.yahoo.com/news/caribou-biosciences-announces-dosing-first-120000815.html?src=rss Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet PrimeNewswire (Top News) Country/Territory United States Date 29/03/23 Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of ... Media name/outlet Bakersfield.com Country/Territory United States Date 29/03/23 URL https://www.bakersfield.com/ap/news/caribou-biosciences-announces-dosing-of-first-patient-in-the-cammouflage-phase-1-trial-of/article_9e6af4e8-88bf-5763-b684-c3beb326ed5e.html Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet BizWire Express Country/Territory India Date 29/03/23 URL www.bizwireexpress.com/showstoryGNW.php?storyid=577381 Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet Fox 4 WDAF TV Country/Territory United States Date 29/03/23 URL https://fox4kc.com/business/press-releases/globenewswire/8797515/caribou-biosciences-announces-dosing-of-first-patient-in-the-cammouflage-phase-1-trial-of-cb-011-an-allogeneic-anti-bcma-car-t-cell-therapy-for-the-treatment-of-relapsed-or-refractory-multiple-myelom Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet CBS4Indy Country/Territory United States Date 29/03/23 URL https://cbs4indy.com/business/press-releases/globenewswire/8797515/caribou-biosciences-announces-dosing-of-first-patient-in-the-cammouflage-phase-1-trial-of-cb-011-an-allogeneic-anti-bcma-car-t-cell-therapy-for-the-treatment-of-relapsed-or-refractory-multiple-myelom Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet WGN-TV Country/Territory United States Date 29/03/23 URL https://wgntv.com/business/press-releases/globenewswire/8797515/caribou-biosciences-announces-dosing-of-first-patient-in-the-cammouflage-phase-1-trial-of-cb-011-an-allogeneic-anti-bcma-car-t-cell-therapy-for-the-treatment-of-relapsed-or-refractory-multiple-myelom Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet KTLA Country/Territory United States Date 29/03/23 URL https://ktla.com/business/press-releases/globenewswire/8797515/caribou-biosciences-announces-dosing-of-first-patient-in-the-cammouflage-phase-1-trial-of-cb-011-an-allogeneic-anti-bcma-car-t-cell-therapy-for-the-treatment-of-relapsed-or-refractory-multiple-myelom Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet FOX 31 News KDVR Country/Territory United States Date 29/03/23 URL https://kdvr.com/business/press-releases/globenewswire/8797515/caribou-biosciences-announces-dosing-of-first-patient-in-the-cammouflage-phase-1-trial-of-cb-011-an-allogeneic-anti-bcma-car-t-cell-therapy-for-the-treatment-of-relapsed-or-refractory-multiple-myelom Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet The Podcast Park Country/Territory Georgia Date 29/03/23 URL lifestyle.thepodcastpark.com/story/48636143/caribou-biosciences-announces-dosing-of-first-patient-in-the-cammouflage-phase-1-trial-of-cb-011-an-allogeneic-anti-bcma-car-t-cell-therapy-for-the Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet 96.7 3WZ-FM Country/Territory United States Date 29/03/23 URL https://lifestyle.3wzfm.com/story/48636143/caribou-biosciences-announces-dosing-of-first-patient-in-the-cammouflage-phase-1-trial-of-cb-011-an-allogeneic-anti-bcma-car-t-cell-therapy-for-the Persons Sundar Jagannath Title Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet WLUS-FM 98.3 Country/Territory United States Date 29/03/23 URL https://lifestyle.us983.com/story/48636143/caribou-biosciences-announces-dosing-of-first-patient-in-the-cammouflage-phase-1-trial-of-cb-011-an-allogeneic-anti-bcma-car-t-cell-therapy-for-the Persons Sundar Jagannath